Eli Lilly and Company (LLY)
A forensic read on Eli Lilly and Company built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and sells pharmaceutical products. Its growth is overwhelmingly driven by its cardiometabolic health franchise, specifically the incretin-based medicines Mounjaro (for type 2 diabetes) and Zepbound (for obesity), which together accounted for 56% of total revenue in FY2025.
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Eli Lilly and Company's actual 10-K/10-Q/8-K filings?
Generate the AI investment read →No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Aug 6, 2026. Forensic signals flag probability, not certainty.